BUSINESSFINANCIAL TIMES WORLD
AbbVie buys Apogee for $10.9bn to acquire inflammatory disease drug
AbbVie acquired Apogee for $10.9 billion to gain an inflammatory disease drug. The deal is AbbVie's largest in over five years and reflects increased M&A activity in the pharmaceutical sector.
Related Signal
Adjacent reporting
- Chiesi Agrees to Buy KalVista Pharmaceuticals for $1.9 Billion
- STAT+: AbbVie to buy Apogee Therapeutics in nearly $11B deal
- Biogen is buying anti-inflammatory drug startup RayThera for up to $1 billion
- STAT+: Pharmalittle: We’re reading about a $10.6 billion GSK deal, an AstraZeneca obesity pill, and more
- GSK just announced its biggest purchase in eight years to rev up cancer portfolio it had previously wound down